CGEM

Cullinan Therapeutics, Inc.

16.81 USD
-2.21 (-11.62%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cullinan Therapeutics, Inc. stock is down -29.9% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30% of the previous 15 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 2 PUTs, 8 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
30 Apr 16:11 21 Jun, 2024 20.00 PUT 400 0
01 May 14:28 19 Jul, 2024 40.00 CALL 200 286
01 May 19:57 19 Jul, 2024 20.00 CALL 162 500
01 May 19:58 19 Jul, 2024 20.00 CALL 38 500
06 May 15:27 19 Jul, 2024 40.00 CALL 235 622
17 May 16:20 18 Oct, 2024 25.00 CALL 250 15
24 May 13:30 17 Jan, 2025 22.50 PUT 50 0
24 May 17:36 19 Dec, 2025 40.00 CALL 100 1
24 May 18:15 19 Dec, 2025 40.00 CALL 40 1
24 May 18:34 19 Dec, 2025 40.00 CALL 60 1

About Cullinan Therapeutics, Inc.

Cullinan Oncology Inc. focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.

  • HC Wainwright & Co.
    Mon Jun 3, 06:08
    buy
    confirm
  • HC Wainwright & Co.
    Fri May 24, 06:54
    buy
    confirm